CYBIN INC

Cybin Inc. unveils new CEO Michael Halstead amid rebranding and JSE regulatory hurdles, yet stays focused on pioneering psychedelic drug delivery and growth.

Helus Pharma’s shift from Cybin Inc. to Nasdaq “HELP” signals a broad biopharma pivot, expanding its serotonergic‑agonist pipeline for mood, anxiety, PTSD and substance‑use disorders.

Explore Cybin Inc., the Toronto‑based psychedelic therapeutics innovator, its market metrics, delivery‑system strategy, and growth prospects amid FDA approvals and investor interest.